Genor Biopharma Co., Ltd.

Genor Biopharma Co., Ltd. logo
🇨🇳China
Ownership
Holding, Subsidiary
Established
2007-12-04
Employees
101
Market Cap
-
Website
http://www.genorbio.com

A Study of [14C]GB491 in Male Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2023-05-16
Last Posted Date
2023-05-16
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
6
Registration Number
NCT05860582
Locations
🇨🇳

Beijing GoBroad Boren Hospital, Beijing, Beijing, China

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

First Posted Date
2023-05-09
Last Posted Date
2023-05-09
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
350
Registration Number
NCT05851014
Locations
🇨🇳

Xingtai People's Hospital, Xingtai, Hebei, China

🇨🇳

Hubei Cancer Hospital, Wuhan, Hubei, China

🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

and more 49 locations

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Phase 1
Conditions
Interventions
First Posted Date
2022-04-20
Last Posted Date
2022-04-20
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
10
Registration Number
NCT05337657
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-04-18
Last Posted Date
2022-08-05
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
120
Registration Number
NCT05332574
Locations
🇦🇺

Genesis Care, Saint Leonards, New South Wales, Australia

🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

🇦🇺

St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia

and more 1 locations

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

First Posted Date
2021-09-23
Last Posted Date
2024-10-10
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
275
Registration Number
NCT05054751
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

🇨🇳

Anhui Provincial Cancer Hospital, Hefei, Anhui, China

and more 51 locations

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2021-06-11
Last Posted Date
2023-05-22
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
460
Registration Number
NCT04923048
Locations
🇦🇺

One Clinical Research Pty Ltd, Mount Pleasant, Western Australia, Australia

🇦🇺

St Vincent's Hospital/The Kinghorn Cancer Centre, Sydney, New South Wales, Australia

🇦🇺

Cabrini hospital, Melbourne, The State Of Victoria, Australia

and more 3 locations

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-05-27
Last Posted Date
2021-05-27
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
87
Registration Number
NCT04905667
Locations
🇨🇳

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangzhou, China

A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients

First Posted Date
2019-11-27
Last Posted Date
2019-11-27
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
24
Registration Number
NCT04179513
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Phase â…  Clinical Study Protocol of GB223 Monoclonal Antibody Injection

First Posted Date
2019-11-26
Last Posted Date
2019-11-26
Lead Sponsor
Genor Biopharma Co., Ltd.
Target Recruit Count
44
Registration Number
NCT04178044
Locations
🇨🇳

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath